Annexin Pharmaceuticals AB is developing an annexin A5 protein to help stop disease progression and prevent limb amputation in peripheral arterial occlusive disease. The protein has therapeutic benefits including anti-inflammatory, antithrombotic and anti-atherosclerotic activity.

Current treatments for peripheral vascular disease (PVD) depend on the cause and severity. These include antithrombotic agents and vasodilators to restore blood flow, and endovascular surgical interventions including stents and balloon angioplasty in occluded vessels.